239 related articles for article (PubMed ID: 24865757)
1. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
2. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
[TBL] [Abstract][Full Text] [Related]
3. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.
Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A
J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883
[TBL] [Abstract][Full Text] [Related]
6. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
Rizzo M
IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM
Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
[TBL] [Abstract][Full Text] [Related]
8. Lomitapide.
Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
[TBL] [Abstract][Full Text] [Related]
9. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
11. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
12. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
13. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.
Blom DJ; Fayad ZA; Kastelein JJ; Larrey D; Makris L; Schwamlein C; Bloeden L; Underberg J;
J Clin Lipidol; 2016; 10(2):273-82. PubMed ID: 27055957
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide.
Giammanco A; Cefalù AB; Noto D; Averna MR
Curr Med Chem; 2020; 27(23):3773-3783. PubMed ID: 30663562
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
Cuchel M; Blom DJ; Averna MR
Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
[TBL] [Abstract][Full Text] [Related]
17. Lomitapide for the treatment of hypercholesterolemia.
Berberich AJ; Hegele RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
[TBL] [Abstract][Full Text] [Related]
18. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.
Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A
J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108
[TBL] [Abstract][Full Text] [Related]
19. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.
Chacra APM; Ferrari MC; Rocha VZ; Santos RD
J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303
[TBL] [Abstract][Full Text] [Related]
20. MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.
Kolovou GD; Kolovou V; Papadopoulou A; Watts GF
J Atheroscler Thromb; 2016 Jul; 23(7):878-83. PubMed ID: 27170061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
